Novo Nordisk AS (LTS:0QIU) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QIU Novo Nordisk AS LTS:0QIU
73 GF Score
Price kr287.43
GF Value kr697.01
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

LTS:0QIU
73GF Score
Novo Nordisk AS LTS:0QIU
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (LTS:0QIU) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of kr287.43 is trading 58.8% below its estimated GF Value™ of kr697.01. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for LTS:0QIU:

  • Interest Expense (Positive):
  • GF Value™: kr697.01 vs. price of kr287.43 (58.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the LTS:0QIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
73GF Score

Get the complete analysis for LTS:0QIU

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr287.43
Price
kr697.01
GF Value